Literature DB >> 19656066

Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

Florencia Pereyra1, Sarah Palmer, Toshiyuki Miura, Brian L Block, Ann Wiegand, Alissa C Rothchild, Brett Baker, Rachel Rosenberg, Emily Cutrell, Michael S Seaman, John M Coffin, Bruce D Walker.   

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) elite controllers are able to control virus replication to levels below the limits of detection by commercial assays, but the actual level of viremia in these individuals is not well defined. Here, we quantify plasma HIV-1 RNA in elite controllers and correlate this with specific immunologic parameters.
METHODS: Plasma HIV-1 RNA levels were quantified in 90 elite controllers with use of a real time reverse-transcriptase polymerase chain reaction assay with a sensitivity of 0.2 copies/mL. HIV-1-specific immune responses and longitudinal CD4(+) T cell counts were examined.
RESULTS: The median plasma HIV-1 RNA level was 2 copies/mL (interquartile range, 0.2-14 copies/mL). A longitudinal analysis of 31 elite controllers demonstrated 2-5-fold fluctuations in viremia in the majority of individuals; 6 had persistent levels below 1 copy/mL. Viremia correlated directly with HIV-1-specific neutralizing antibodies and Western blot reactivity but not with CD8(+) T cell responses. Absolute CD4(+) T cell decrease was more common among individuals with detectable viremia (P = .04).
CONCLUSIONS: Low-level viremia is present in the majority of elite controllers and is associated with higher HIV-1-specific antibody responses. Absolute CD4(+) T cell loss is more common among viremic individuals, suggesting that even very low-level viremia has negative consequences over time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656066      PMCID: PMC3725728          DOI: 10.1086/605446

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Authors:  Toshiyuki Miura; Chanson J Brumme; Mark A Brockman; Zabrina L Brumme; Florencia Pereyra; Brian L Block; Alicja Trocha; Mina John; Simon Mallal; P Richard Harrigan; Bruce D Walker
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

2.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

3.  CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load.

Authors:  Adriana Andrade; Justin R Bailey; Jie Xu; Frances H Philp; Thomas C Quinn; Thomas M Williams; Stuart C Ray; David L Thomas; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

4.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

Authors:  Jason B Dinoso; Scott Y Kim; Robert F Siliciano; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

5.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

6.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

7.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Authors:  Stephen A Migueles; Christine M Osborne; Cassandra Royce; Alex A Compton; Rohan P Joshi; Kristin A Weeks; Julia E Rood; Amy M Berkley; Jonah B Sacha; Nancy A Cogliano-Shutta; Margaret Lloyd; Gregg Roby; Richard Kwan; Mary McLaughlin; Sara Stallings; Catherine Rehm; Marie A O'Shea; JoAnn Mican; Beverly Z Packard; Akira Komoriya; Sarah Palmer; Ann P Wiegand; Frank Maldarelli; John M Coffin; John W Mellors; Claire W Hallahan; Dean A Follman; Mark Connors
Journal:  Immunity       Date:  2008-12-08       Impact factor: 31.745

8.  Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes.

Authors:  Huabiao Chen; Alicja Piechocka-Trocha; Toshiyuki Miura; Mark A Brockman; Boris D Julg; Brett M Baker; Alissa C Rothchild; Brian L Block; Arne Schneidewind; Tomohiko Koibuchi; Florencia Pereyra; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

9.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children.

Authors:  M E Feeney; K A Roosevelt; Y Tang; K J Pfafferott; K McIntosh; S K Burchett; C Mao; B D Walker; P J R Goulder
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  124 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Authors:  Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

4.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  CD4 T-cell regeneration in HIV-1 elite controllers.

Authors:  Yue Yang; Maha Al-Mozaini; Maria J Buzon; Jill Beamon; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos; Eric S Rosenberg; Florencia Pereyra; Xu G Yu; Mathias Lichterfeld
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

6.  The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Authors:  Zaza M Ndhlovu; Eleni Stampouloglou; Kevin Cesa; Orestes Mavrothalassitis; Donna Marie Alvino; Jonathan Z Li; Shannon Wilton; Daniel Karel; Alicja Piechocka-Trocha; Huabiao Chen; Florencia Pereyra; Bruce D Walker
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

7.  Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology.

Authors:  Joshua A Walker; Andrew D Miller; Tricia H Burdo; Michael S McGrath; Kenneth C Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

8.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Authors:  María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

9.  HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.

Authors:  Alan Landay; Elizabeth T Golub; Seema Desai; Jinbing Zhang; Val Winkelman; Kathryn Anastos; Helen Durkin; Mary Young; Maria C Villacres; Ruth M Greenblatt; Philip J Norris; Michael P Busch
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

10.  Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.

Authors:  Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.